Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529529 · ClinicalTrials.gov registry record · Phase 3
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
A Phase 3 study of Asthma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 805
- Enrollment target
- 20
- Study locations
NCT00529529 is a Phase 3 study of Asthma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 805 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00529529, a Phase 3 study of Asthma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 805 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily \[od\]), compared with salmeterol (50 μg twice a day \[b.i.d.\]), over 26 weeks, in patients with moderate to severe persistent asthma.
Conditions Studied
Interventions
- DRUG Indacaterol 300 μg
- DRUG Placebo to indacaterol
- DRUG Salmeterol 50 μg
- DRUG Placebo to salmeterol
Study Locations (20)
California
- Novartis Investigator Site - Encinitas
- Novartis Investigator Site - Huntington Beach
- Novartis Investigator Site - Long Beach
- Novartis Investigator Site - Long Beach
- Novartis Investigator Site - Los Angeles
- Novartis Investigator Site x 2 sites - Oakland
- Novartis Investigator Site - Orange
- Novartis Investigator Site - Palmdale
- Novartis Investigator Site - San Diego
- Novartis Investigator Site - San Diego
- Novartis Investigator Site - Walnut Creek
Colorado
- Novartis Investigator Site - Denver
- Novartis Investigator Site - Denver
- Novartis Investigator Site - Englewood
- Novartis Investigator Site - Lakewood
Florida
- Novartis Investigator Site - Brandon
- Novartis Investigator Site - Largo
- Novartis Investigator Site - Miami
Arizona
- Novartis Investigator Site - Glendale
- Novartis Investigator Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 805 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529529
The ClinicalTrials.gov registry entry for NCT00529529 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 805 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (48% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Indacaterol 300 μg is the first listed.
NCT00529529 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00529529 about?
NCT00529529 is a clinical study titled "Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma". This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily \[od\]), compared with salmeterol (50 μg twice a day \[b.i.d.\]), over 26 weeks, in patients with moderate to severe persistent asthma.
What is the current status of trial NCT00529529?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 805 participants. The study started on 2007-09. Estimated completion is 2008-08.
What conditions does trial NCT00529529 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00529529?
The interventions under investigation include: Indacaterol 300 μg (DRUG), Placebo to indacaterol (DRUG), Salmeterol 50 μg (DRUG), Placebo to salmeterol (DRUG).
Who is sponsoring clinical trial NCT00529529?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00529529 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.